Exondys 51

Chemical Nameeteplirsen
Dosage FormInjection (intravenous; 100 mg/2 mL, 500 mg/10 mL)
Drug ClassOligonucleotides
SystemMusculoskeletal
CompanySarepta Therapeutics Inc.
Approval Year2016

Indication

  • For the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.
Last updated on 12/23/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Exondys 51 (eteplirsen) Prescribing Information 2020Sarepta Therapeutics, Inc., Cambridge, MA